Dapagliflozin treatment in lupus nephritis patients did not significantly alter bone turnover markers over one year.
Quantitative computed tomography showed modest improvement in lumbar spine L3 bone density, but overall bone mineral density decline was nonsignificant after adjustment.
The study supports the renal and cardiovascular benefits of SGLT2 inhibitors without evident harm to bone health in this vulnerable population.
Background
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
